Abstract
Transfusion by blood platelets is established therapy for patients with bleeding phenotypes or diseases. An insufficient supply of platelet concentrate is being caused by the unstable properties of platelets that should keep at room temperature and are useful within only 3-4 days, which is different from case of red blood cells. Embryonic stem cells (ESCs) could potentially compensate for the lack of availability for blood platelets used in transfusions. Recently established induced pluripotent stem (iPS) cells could be an alternative source for generating platelets in vitro replacing of donor blood that may cause various infectious diseases.
